Ultragenyx Pharmaceutical Overview
Ultragenyx Pharmaceutical (RARE) has a ROE of 201.52%, above the Healthcare sector average of 21.3%.
Get informed when a big investor buys or sells
+ Follow201.52%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, RARE shows a ROE of 201.52%. That is above the Healthcare sector average of 21.3%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.3%. Ultragenyx Pharmaceutical is at 201.52%, which is higher that average. That is roughly 846.0% above the sector mean. Use the comparison chart on this page to see how RARE stacks up against individual peers as well.
Check the historical chart to see whether RARE's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Ultragenyx Pharmaceutical with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Ultragenyx Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 201.52%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.3%, while RARE is at 201.52%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
